INOVIQ Limited announced excellent results from an independent clinical validation study of its SubB2M/CA15-3 test for breast cancer detection. The study showed high accuracy (87%), sensitivity (81%), and specificity (93%) for INOVIQ's SubB2M test, outperforming a leading approved CA15-3 test. The study showed high accuracy ("87%), sensitivity (81%),and specificity (93%) for INovIQ's SubB2M testing, outperforming a leading approvedCA15-3 test.

The outstanding results from this independent clinical validation study of its subB2M/CA15 -3 blood test detected all-stages of breast cancer with 81% sensitivity and 93% specificity, outperforming a leading CA15-3 test. These positive results support the commercial potential of simple, cost-effective SubB2M/CA 15-3 test for screening and monitoring of breast cancer. INOVIQ intends to present these data and development plans to potential partners and KOLs to advance commercial discussions for its SubB2M/CA125 and SubB2M multi-cancer tests.

INOVIQ's disruptive SubB2M technology is an engineered protein that detects the pan-cancer biomarker Neu5Gc, found in multiple human cancers. SubB2M tests are designed to enhance the sensitivity, specificity and clinical utility of existing tumour marker tests routinely used for cancer detection and monitoring, such as CA15-3 for breast cancer, CA125 for ovarian cancer, PSA for prostate cancer and CA19.9 for pancreatic cancer. INOVIQ intends To present these data and development plans To potential partners and KOLs To advance commercial discussions for its Sub B2M/CA15- 3, SubB2M/CA125 and SubB2M multiple-cancer tests.

INOV IQ's disruptive SubB2M Technology is an engineered protein that detects The pan-cancer biomarker NeU5Gc, found in many human cancers. SubB2 M tests are designed to enhance the sensitive, specificity and clinical utility of current tumour marker tests routinely used to monitor breast cancer treatment response and disease recurrence.